View printer-friendly version

Brisbane, Australia, 30 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Coviu, Australia’s leading telehealth platform, have completed an initial integration of ResAppDx-EU into Coviu’s telehealth platform. This integration will allow clinicians using Coviu’s platform to perform a remote respiratory assessment using ResApp’s clinically validated and Therapeutic Goods Administration (TGA) approved diagnostic test.

ResApp and Coviu have signed a binding commercial terms sheet and have agreed upon a per test fee for the use of ResAppDx-EU on Coviu’s telehealth platform. The per test fee received by ResApp is within the previously targeted range of $5-10 per test. The non-exclusive licence will have an initial term of two years and may be extended by mutual agreement. Either party may terminate the licence by providing 60 days written notice. Coviu and ResApp intend to rapidly progress to a formal licence agreement and plan to have ResAppDx-EU available for use by all clinicians on Coviu’s platform within a few months.

A spinout from CSIRO’s Data61, Coviu’s telehealth platform makes it easy for healthcare providers to offer their services directly to patients via video consultation whilst incorporating a range of digital assessment tools to assist in virtual consults. Coviu’s platform powers the Australian government-funded healthdirect Video Call service and has almost 10,000 active mental and allied health professionals, specialists and a growing number of general practitioners (GPs) using the service.

ResAppDx-EU is a software application used by clinicians to diagnose the most common respiratory diseases. The software uses machine learning algorithms that analyse a patient’s cough sounds to diagnose lower respiratory tract diseases such as pneumonia and asthma exacerbations. ResAppDx-EU is CE Marked in the European Union and Therapeutics Goods Administration (TGA) approved in Australia.

“The COVID-19 pandemic has put many healthcare workers at risk of contracting the highly contagious disease. Patients who may suspect that they have COVID-19, but are in fact unwell with another respiratory condition, are also putting themselves at risk if they attend an overworked clinic. In response to the COVID-19 crisis, the federal government has announced that from today, Medicare will reimburse all telehealth consultations, giving every Australian the opportunity to consult with their doctor from the comfort and safety of their own home,” said Dr Silvia Pfeiffer, CEO and co-founder of Coviu. “By using ResAppDx-EU inside our telehealth platform, clinicians can make more informed decisions when triaging the many patients who present with respiratory symptoms, which is especially important as the COVID-19 pandemic starts to coincide with the winter flu season.”

Tony Keating, CEO and Managing Director of ResApp, added, “Telehealth is a key component in Australia’s strategy to contain COVID-19, with the country now moving to a whole-of-population telehealth system. Coviu’s web-based easy-to-use telehealth platform is experiencing exponential growth and is designed to integrate a range of digital tools to enhance the clinicians’ capabilities. This makes them an ideal partner to offer ResAppDx-EU. We are pleased to have agreed commercial terms with Coviu which will see ResAppDx-EU widely-available in Australia.”

###

About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp’s smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au.

About Coviu Global Pty Ltd
Coviu Global Pty Ltd is Australia’s leading telehealth software company and a spinout of CSIRO’s Data61, offering a video consultation software to healthcare businesses. It brings the specific workflows and tools necessary for healthcare into an online video call while satisfying regulatory requirements around security and privacy. For more information, please visit www.coviu.com.

Contacts for ResApp Health
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000

© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.